| Compound | 5-Amino-1MQ |
|---|---|
| Category | NNMT inhibitor (small molecule) |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers 5-Amino-1MQ, a nnmt inhibitor (small molecule), graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied in mice for fat-mass reduction without altered food intake.
Mechanism of Action
NNMT inhibition is proposed to raise cellular SAM and NAD+ flux, shifting adipocyte metabolism from fat storage toward energy expenditure.
Research and Evidence
Mouse studies reported reduced adiposity; human data do not exist.
Safety and Side Effects
No human safety data.
Frequently Asked Questions
What is the evidence tier of 5-Amino-1MQ?
5-Amino-1MQ is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is 5-Amino-1MQ an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for 5-Amino-1MQ?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for 5-amino-1MQ studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.